Trogenix
2 known investors
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system. Its lead program, TGX-007, is a gene therapy for glioblastoma in a Phase I/II clinical trial, with potential applications in solid tumours and regenerative medicine.
Investors · 2
.jpeg){kind=logo}
Frequently asked questions
- What does Trogenix do?
- Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system. Its lead program, TGX-007, is a gene therapy for glioblastoma in a Phase I/II clinical trial, with potential applications in solid tumours and regenerative medicine.
- Who are Trogenix's investors?
- Trogenix's investors include AIN Ventures, IQ Capital.